Objective?To study the effect of telmisartan combined with nifedipine controlled-release tablets on blood glucose and inflammation in patients with diabetes and hypertension. Methods?230 patients with diabetes and hypertension admitted to Caoshi Yuhe Community Health Service Center of Qingyang District from April 2018 to June 2020 were selected and divided into the control group and the test group according to the random number table, 115 cases in each group. Patients in the control group were treated with nifedipine controlled-release tablets, and patients in the test group were treated with telmisartan on the basis of the control group. Patients in both groups were treated for 5 weeks. Compared the clinical efficacy of the two groups of patients after treatment, the changes in blood glucose levels and inflammation before and after treatment. Results?After treatment, the total clinical effective rate of the test group was significantly higher than that of the control group; the fasting blood glucose (FPG), 2 h postprandial blood glucose (2 h PG), and glycosylated hemoglobin (HbA1c) levels of the two groups were all significantly lower than before treatment (all P<0.05); after treatment, there was no statistically difference in the comparison of each index between the two groups (all P>0.05);ater treatment, the serum tumor necrosis factor-ɑ(TNF-ɑ), C-reactive protein (CRP) and homocysteine (Hcy) levels of the two groups of patients were lower than before treatment, and the test group was lower than the control group (all P<0.05). Conclusion?Telmisartan combined with nifedipine controlled-release tablets can improve the blood glucose level of patients with diabetes and hypertension by inhibiting the inflammatory response, and improve clinical efficacy